- ¥136bn
- ¥128bn
- ¥19bn
Table: Peptidream -Q1 group results (IFRS)
Table: Peptidream -2021 parent results
Table: Peptidream -2021 parent forecast
Table: Peptidream - 9-MTH parent results
Table: Peptidream - 6-MTH parent results
Brief: Alnylam, PeptiDream Enter Into Collaboration Agreement
Brief: Takeda to pay Peptidream up to $3.5 bln after partnership expansion
Table: Peptidream - Q1 parent results
Table: Peptidream -2020 parent results
Table: Peptidream -2020 parent forecast
Table: Peptidream - 9-MTH parent results
Japan's Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments
Table: Peptidream - 6-MTH parent results
Japan's PeptiDream to work with Merck in developing COVID-19 therapies
Table: Peptidream - Q1 parent results
Brief: Biohaven Receives FDA May Proceed Letter To Begin Phase 2 Trial Of Intranasal Vazegepant To Treat Lung Inflammation After Covid-19 Infection
Table: Peptidream -2019 parent results
Focus: Biotech-for-hire PeptiDream charts new path and becomes short target
Focus: Biotech-for-hire PeptiDream charts new path and becomes short target